Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Saccharin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.79 |
| ▸ | CA9 | Q16790 | 6/20 | 0.79 |
| ▸ | CA2 | P00918 | 5/20 | 0.79 |
| ▸ | CA1 | P00915 | 3/20 | 0.79 |
| ▸ | CA7 | P43166 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | BCHE | P06276 | 1/20 | 0.79 |
| ▸ | CA4 | P22748 | 1/20 | 0.79 |
| ▸ | CA6 | P23280 | 1/20 | 0.79 |
| ▸ | CA5A | P35218 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.79 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.79 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saccharin SCHEMBL27585928 | 1.00 | CA12 (0.79) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL3661332 | 0.98 | CA12 (0.81) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL299663 | 0.98 | CA12 (0.81) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL10380910 | 0.98 | CA12 (0.81) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL27598742 | 0.96 | CA12 (0.79) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL28969625 | 0.96 | CA12 (0.79) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL10400264 | 0.95 | CA12 (0.76) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL10338383 | 0.92 | CA12 (0.71) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL29733582 | 0.91 | CA12 (0.76) | CA12CA9CA2CA1CA7 | |
| Saccharin SCHEMBL10899217 | 0.91 | CA12 (0.96) | CA12CA9CA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150283157-A1 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS | OPKO HEALTH INC (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2632259-A1 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS | OPKO Health, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| CN-103269585-A | Hypersulfated disaccharides to treat elastase related disorders | OPKO HEALTH INC | 2013-08-28 | — | — | CN | disclosed |
| US-20130203695-A1 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS | OPKO HEALTH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012058424-A1 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS | OPKO HEALTH, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283157-A1 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS | ELANE, SERPINB1, CELA1 | NTRK3 4829/4885CA12 525/4885CA9 1680/4885 |
| US-20130203695-A1 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS | ELANE, SERPINB1, CELA1 | NTRK3 4827/4885CA12 530/4885CA9 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.